SRC and cancer: For example, recent studies have shown that inhibiting the CX3CL1‒CX3CR1 axis, particularly with drugs such as the Src inhibitor saracatinib, can block the chemotactic effect of CX3CL1 and reduce tumor metastasis in other cancers [37, 38].